 The pre-planned interim analysis for the Independent Data Monitoring Committee IDMC showed that the difference in progression-free survival PFS between treatment arms MPRR and MPpp the defined primary comparative analysis for this study surpassed the pre-specified OBrien-Fleming boundary for superiority. The IDMC recommended the release of this information to the sponsor and also recommended that all patient and physician study participants receive information concerning the full findings of the MM-015 interim analysis. Therefore, due to these recommendations from the IDMC, treatment-arm codes were sent to the clinical trial centers to unblind the treatment arms of their study subjects once the amended protocol was reviewed and approved by the respective country Health Authorities and Ethics Committees. Subject participation in the MM-015 study continued after unblinding to obtain long-term data for all study endpoints, including overall survival. 